Evidence map›Paper›PMID 42513493›Full record

ArticleJournal of clinical medicine2026

Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey.

Derya Demirtas, Elif Suyani, Alper Koc, Bilal Aygun, Zeynep Tugba Karabulut, Nurhilal Buyukkurt, Cagatay Unsal, Didar Yanardag Acik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Derya DemirtasDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.ORCID 0000-0001-9449-8759
Elif SuyaniDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.
Alper KocDepartment of Hematology, Elazıg Fethi Sekin City Hospital, 23280 Elazıg, Turkey.ORCID 0000-0003-0844-2658
Bilal AygunDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.
Zeynep Tugba KarabulutDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.
Nurhilal BuyukkurtDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.ORCID 0000-0002-0895-4787
Cagatay UnsalDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.
Didar Yanardag AcikDepartment of Hematology, Adana City Training and Research Hospital, University of Health Sciences, 01230 Adana, Turkey.ORCID 0000-0001-7282-0188

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ABVDadvanced-stage diseaseclassical Hodgkin Lymphomaoverall survivalprogression-free survivalreal-world outcomes

Identifiers

PMID42513493
PMCPMC13412601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.